Followers | 14 |
Posts | 1446 |
Boards Moderated | 0 |
Alias Born | 02/28/2011 |
Monday, August 21, 2017 9:41:53 AM
I'd highly recommended you listen to the call from last week, just click the link and register. all of the company's most recent 2Q highlights are from a PR on August 14th (see their website).
Conference Call - http://public.viavid.com/player/index.php?id=125868
Canada - during the company's conference call on August 16th, they updated shareholders about the option to treat people in Canada. quick answer the CEO gave us was that the process to get approval in Canada would take as long as the US Phase 3 trial so at the moment, the company is focusing all efforts on phase 3. They said they're still in contact and discussions with Canada's ministry of health.
Israel - this has been very important as the company moves forward. currently, they're in negotiations with the ministry of health and still working to get hospital exemption status. the CEO wasn't too forthcoming with information during the conference call because it appears they're very close to an agreement. I think his lack of info was for legal purposes. the CEO said they would initially treat 3-4 patients and if the process and patients are ok, they'll move onto to treating others. Now the 50-60 patients is from patients who've already signed up to receive treatment. The CEO also stated in the conference call that if patients are treated this year, the company will be profitable in Q1 2018. Also, keep in the mind the company has just under $7M in cash and NO DEBT.. so, if they treat 5 patients, they'll be profitable. It won't be a lot but it says a lot about the company.
Phase 3 - for this process, yes, the enrollment period would take about 3-4 months as the bone aspiration will occur 5 weeks prior to the first treatment. don't quote me on this but when treatment is available during hospital exemption status, they're treating anyone who wants to be treated. I believe there's no enrollment, if someone with ALS wants to be treated, they'll have to pay for the service. I assume the company and hospital will take proper safety protocols and patients will have to sign waivers, etc. but I believe when a treatment is available under this status, it's like receiving regular treatment.
click link for patient update hosted by NEALS - skip to 18:30 of the video when they discuss P3 design and details. https://www.neals.org/for-people-with-als-caregivers/educational-webinars/nurown-clinical-development-program-promising-phase-2-results-phase-3-study
hopefully this answers your questions? let me know if you have anymore!
Recent BCLI News
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 09/17/2024 07:32:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/16/2024 08:36:41 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/09/2024 04:15:04 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 08/28/2024 09:01:02 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/16/2024 11:00:19 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 12:01:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 11:15:21 AM
- Form PRER14A - Preliminary Proxy Soliciting materials • Edgar (US Regulatory) • 08/06/2024 08:59:18 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 08/05/2024 09:11:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 08:05:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/24/2024 08:05:18 PM
- BCLI Update - Progress Supports Our 10x Plus Value Range Potential • PR Newswire (Canada) • 07/24/2024 12:30:00 PM
- BCLI Update - Progress Supports Our 10x Plus Value Range Potential • PR Newswire (US) • 07/24/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/19/2024 08:05:57 PM
- Initiation - Potential 10x Return on Successful Phase 3b. Promising Post Hoc and Biomarker Analysis Underpins Our NurOwn® Clinical Effectiveness Expectation • PR Newswire (US) • 06/14/2024 04:01:00 PM
- Initiation - Potential 10x Return on Successful Phase 3b. Promising Post Hoc and Biomarker Analysis Underpins Our NurOwn® Clinical Effectiveness Expectation • PR Newswire (Canada) • 06/14/2024 04:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 10:05:20 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM